Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
暂无分享,去创建一个
[1] J. Olson,et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Goodwin,et al. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study , 2015, Breast Cancer Research.
[3] N. Harbeck,et al. WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial , 2013, Trials.
[4] H Tesch,et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] A. Bardia,et al. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.
[6] A. Bardia,et al. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. , 2016, Breast.
[7] Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Collins,et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). , 2014, The Cochrane database of systematic reviews.
[9] M. Piccart,et al. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). , 2016, European journal of cancer.
[10] T. Yamanaka,et al. Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer , 2013, International Journal of Clinical Oncology.
[11] H. Tsuda,et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study , 2013, Cancer science.
[12] Carsten Denkert,et al. Strategies for developing Ki67 as a useful biomarker in breast cancer. , 2015, Breast.
[13] J. Albanell,et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] D. Amadori,et al. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[16] Christos Hatzis,et al. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy , 2015, Modern Pathology.
[17] D. Cutter,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.
[18] John M S Bartlett,et al. An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.
[19] J. Olson,et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Dowsett,et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] K. Hunt,et al. Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study , 2017, Annals of Surgical Oncology.
[22] A. Giobbie-Hurder,et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.
[23] J. Forbes,et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.
[24] I. Bièche,et al. Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] John M S Bartlett,et al. Abstract P1-01-01: Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration , 2016 .
[26] A. Ashworth,et al. Molecular response to aromatase inhibitor treatment in primary breast cancer , 2007, Breast Cancer Research.
[27] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[28] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[29] J. J. van der Hoeven,et al. [70-Gene signature as an aid to treatment decisions in early-stage breast cancer]. , 2017, Nederlands tijdschrift voor geneeskunde.
[30] R. Peto,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.
[31] Karen A Gelmon,et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Reed,et al. Primary endocrine therapy as a treatment for older women with operable breast cancer - a comparison of randomised controlled trial and cohort study findings. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[33] Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. , 1982, British medical journal.
[34] S. Loi,et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.
[35] K. Gelmon,et al. Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.
[36] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[37] Jeffrey M. Rosen,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.
[38] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2018, The New England journal of medicine.
[39] H. Iwata,et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[40] M. Dowsett,et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] J. Thigpen. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .
[42] J. Olson,et al. Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders. , 2009 .
[43] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] A. Seidman. Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis , 2006 .
[45] M. Cristofanilli,et al. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer , 2016, Breast Cancer Research and Treatment.
[46] V. Semiglazov. RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer. , 2015, Journal of the National Cancer Institute. Monographs.
[47] Saeed Sadeghi,et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Jingqin Luo,et al. Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.
[49] L. Cavanna,et al. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] J. Baselga,et al. MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. , 2016 .
[51] R. Schiff,et al. Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study , 2011, Clinical Cancer Research.
[52] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Didier Verhoeven,et al. Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial , 2013, Journal of the National Cancer Institute.
[54] M. Dowsett,et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] I. Bièche,et al. Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial , 2016 .
[56] M. Ellis,et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. , 2003, Cancer research.
[57] Aleix Prat Aparicio. Comprehensive molecular portraits of human breast tumours , 2012 .
[58] David Cameron,et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole , 2008, Breast Cancer Research and Treatment.
[59] V. Semiglazov,et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer , 2007, Cancer.
[60] M. Dowsett,et al. Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039) , 2014, Clinical Cancer Research.
[61] U. Chetty,et al. Indications for primary tamoxifen therapy in elderly women with breast cancer , 1992, The British journal of surgery.
[62] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[63] Christopher A. Miller,et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers , 2016, Nature Communications.
[64] Gao Hai-feng,et al. Proliferation marker Ki-67 in early breast cancer , 2009 .
[65] J. Bradbeer,et al. Primary treatment of breast cancer in elderly women with Tamoxifen. , 1983, Clinical oncology.
[66] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] S. Paik,et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] P. Diest,et al. Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours , 2016, Histopathology.
[69] R. Hawkins,et al. RELATION BETWEEN IMMUNOCYTOCHEMICAL ESTIMATION OF OESTROGEN RECEPTOR IN ELDERLY PATIENTS WITH PRIMARY BREAST CANCER AND RESPONSE TO TAMOXIFEN , 1989, The Lancet.
[70] J. Balko,et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.
[71] A. Ruíz,et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer , 2012, Clinical and Translational Oncology.
[72] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[73] B. Bullen,et al. Removable subcuticular skin suture in acute appendicitis: a prospective comparative clinical trial. , 1982 .
[74] C. Cordiner,et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery , 2014, Breast Cancer Research and Treatment.
[75] S. Chandarlapaty,et al. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. , 2017, Cancer discovery.
[76] Christopher A. Miller,et al. Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation , 2016, Nature Communications.
[77] V. Valero,et al. Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer , 2010, Clinical Cancer Research.
[78] John M S Bartlett,et al. An international study to increase concordance in Ki67 scoring , 2015, Modern Pathology.
[79] M. Mathieu,et al. Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[80] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[81] M. Dowsett,et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer , 2015, Science Translational Medicine.
[82] M. Ellis,et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. , 2016, The Lancet. Oncology.
[83] J. Schilder,et al. Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH) , 2016 .
[84] R. Nicholson,et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study , 2012, Breast Cancer Research and Treatment.
[85] E. Mardis,et al. Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC) , 2016 .
[86] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[87] A. Luini,et al. A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer , 2013, Breast Cancer Research.
[88] Atsushi Arakawa,et al. Ki67 Heterogeneity in Estrogen Receptor–Positive Breast Cancers , 2016, International journal of surgical pathology.
[89] A. Thompson,et al. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial , 2015, Breast Cancer Research and Treatment.
[90] R. Greil,et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.